Abstract. We previously identified TSC22D2 (transforming growth factor β-stimulated clone 22 domain family, member 2) as a novel cancer-associated gene in a rare multi-cancer family. However, its role in tumor development remains completely unknown. In this study, we found that TSC22D2 was significantly downregulated in colorectal cancer (CRC) and that TSC22D2 overexpression inhibited cell growth. Using a co-immunoprecipitation (co-IP) assay combined with mass spectrometry analysis to identify TSC22D2-interacting proteins, we demonstrated that TSC22D2 interacts with pyruvate kinase isoform M2 (PKM2). These findings were confirmed by the results of immunoprecipitation and immunofluorescence assays. Moreover, overexpression of TSC22D2 reduced the level of nuclear PKM2 and suppressed cyclin D1 expression. Collectively, our study reveals a growth suppressor function of TSC22D2 that is at least partially dependent on the TSC22D2-PKM2-cyclinD1 regulatory axis. In addition, our data provide important clues that might contribute to future studies evaluating the role of TSC22D2.
Introduction
In a previous study, we performed a genome-wide linkage analysis of 24 core family members in a rare multi-cancer family. The family included 103 members spanning six generations, and 15 members had been diagnosed with various tumor types, including colorectal cancer (CRC), breast cancer, endometrial carcinoma and gastric cancer. The disease susceptibility locus in this family was mapped to chromosome 3q24-26. A novel mutant in the TSC22D2 gene located in chromosome band 3q24-26 co-segregated with the cancer phenotype, as demonstrated by exome sequencing (1) .
TSC22D2 is a member of the TSC-22 domain family comprising putative transcription factors that are characterized by a carboxy-terminal leucine zipper and an adjacent TSC-box. However, there are few studies describing TSC22D2, and its role in tumor development remains largely unknown.
Accumulating evidence shows that many TSC22D2 family proteins interact with other proteins to form macromolecular complexes and are involved in a broad range of biological processes. For instance, TSC22D1 (referred as TSC-22) can suppress tumor growth by binding to p53 (2) and can enhance TGF-β signaling by associating with Smad4 (3); TSC22D3 (usually called GILZ) plays multiple biological functions dependent on its interaction with other proteins, including NF-κB, Ras and p53 (4) (5) (6) . Accordingly, the identification of the TSC22D2-associated proteins or macromolecular complexes is important to precisely understand the underlying mechanism of TSC22D2 in human carcinogenesis.
In this study, we investigated the role of TSC22D2 in colorectal cancer, the most common malignancy in the multi-cancer family. We found TSC22D2 was significantly downregulated in CRC. Further functional study showed that TSC22D2 overexpression can inhibit CRC cell growth. To precisely define the underlying mechanism by which TSC22D2 influenced CRC cell growth, we used co-immunoprecipitation (co-IP) and mass spectrometry approaches to identify the proteins or macromolecular complexes that
TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal cancer
FANG LIANG [1] [2] [3] interact with TSC22D2, and gained 142 candidate TSC22D2-binding proteins that were associated with a variety of cellular processes. Moreover, we determined that TSC22D2 physically associates with pyruvate kinase isoform M2 (PKM2), a glycolytic enzyme reported to be associated with the growth and survival of multiple cancer cell types (7) (8) (9) , and demonstrated that TSC22D2 overexpression reduces nuclear PKM2 levels and represses the expression of cyclin D1 (a downstream target gene of nuclear PKM2). Plasmid construction. The full length TSC22D2 gene was cloned into the pIReSneo3-Flag vector with NheⅠ and StuⅠ (Takara, Dalian, China) sites. The TSC22D2 gene was amplified using the following primers: TSC22D2 sense primer (5'-ACG TGCTAGCGCCACCATGTCCAAGATGCCGGCCAA-3'), TSC22D2 anti-sense primer (5'-ACTGAGGCCTTTATGCTG AGGAGACATTCG-3'). Full-length PKM2 was generously provided by Professor Xianghuo He (Shanghai Medical College, Fudan University, Shanghai, China) and has been previously described (10) .
Materials and methods

CRC
Cell lines and cell culture. The SW480 (human colorectal carcinoma) and HeK293 (human embryonic kidney) cell lines were cultured in Dulbecco's modified eagle's medium (Life Technologies, Grand Island, ny, USA) with 10% fetal bovine serum (FBS) supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin. The HeLa human cervical carcinoma cells were grown in 1640 medium (Life Technologies) supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were transfected using the Lipofectamine 3000 reagent (Life Technologies) according to the manufacturer's instructions. HeK293, SW480 and HeLa cells stably expressing Flag-tagged TSC22D2 (Flag-TSC22D2) or the control vector (Flag-nC) were obtained by puromycin (600-1,000 ng/ml) (Life Technologies) selection for one month. All cells were maintained under standard culture conditions (37˚C, 5% Co 2 ).
RNA isolation and quantitative real-time PCR. Total RnAs were isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and were converted to cDnA using the GoScript™ Reverse Transcription System (Promega, Madison, WI, USA) according to the manufacturer's instructions. All real-time PCR reactions were performed with SyBR Green (Takara) using the Bio-Rad CFX Connect Real-Time system (Bio-Rad, Hercules, CA, USA). The following PCR program was used: denaturation at 95˚C for 30 sec, followed by 40 cycles consisting of denaturation at 95˚C for 5 sec, annealing at 60˚C for 30 sec, and extension at 72˚C for 30 sec. A melting curve analysis was applied to assess the specificity of the amplified PCR products. The amount of each target gene was quantified by the comparative C T method using GAPDH as the normalization control. The following primers were synthesized from Life Technologies and used to amplify TSC22D2, CCnD1 and GAPDH: TSC22D2 forward primer (5'-TGAT GGTGATGAAGACAGTGC-3'), TSC22D2 reverse primer (5'-GGGTTGGGAGTTGGGATAAT-3'); CCnD1 forward primer (5'-CAACCTCCTCAACGACC-3'), CCnD1 reverse primer (5'-CTTCTGTTCCTCGCAGAC-3'); GAPDH forward primer (5'-AACGGATTTGGTCGTATTGG-3'), GAPDH reverse primer (5'-TTGATTTTGGAGGGATCTCG-3'). All experiments were carried out in triplicate.
Total protein, subcellular fractionation and western blot analysis. nuclear and cytosolic extracts were fractionated using the ne-PeR nuclear and cytoplasmic extraction kit (Thermo Scientific, Bremen, Germany) according to the manufacturer's protocol. To isolate total protein, cells were harvested by scraping and transferred to SDS sample buffer supplemented with a protease inhibitor cocktail and the PhosSToP phosphatase inhibitor (Roche, Pleasanton, CA, USA). equal levels of protein from the samples were separated using SDS-PAGe gel electrophoresis and transferred to a PVDF membrane (Millipore Corp., Billerica, MA, USA). The membrane was blocked with PBST containing 5% skim milk for 1 h and then incubated overnight with the indicated primary antibodies at 4˚C. The membrane was washed three times in PBST and subsequently incubated with an HRP-conjugated secondary antibody for 2 h at 37˚C. The membranes were stripped of the primary antibodies and re-probed with additional antibodies as necessary. Bound antibodies were visualized using the enhanced chemiluminescence kit (Millipore).
The following antibodies were used in this study: monoclonal mouse anti-Flag (F1804, Sigma, St. Louis, Mo, USA), anti-HA (H3663, Sigma), polyclonal rabbit anti-human TSC22D2 (AV39137, Sigma), polyclonal rabbit anti-human PKM2 (Cell Signaling, Danvers, MA, USA) and anti-CCnD1 (Cell Signaling). An antibody against GAPDH (Cell Signaling) served as an endogenous control for equal loading, and anti-H3 (Beyotime, China) served as a nuclear control.
Cell proliferation assays. Cell proliferation was measured by counting viable cells using the Z2 Particle Counter and Size Analyzer Beckman Coulter (Miami, FL, USA). Briefly, SW480 and HeLa cells stably expressing Flag-tagged TSC22D2 (Flag-TSC22D2) or the control vector (Flag-nC) were seeded at 1.2x10 4 cells per well in 24-well plates in quadruplicate, the number of viable cells in each well was measured at 0, 1, 2, 3, 4 and 5 days.
Colony formation assays. For the colony formation assays, SW480 and HeLa cells were seeded in a 6-well plate at a density of 500 and 200 cells per well respectively, and incubated at 37˚C with 5% Co 2 for 2 weeks. The medium was changed every 3-4 days. At the end of the incubation, the medium was removed, and the cells were washed twice with PBS, fixed with 4% paraformaldehyde for 20 min, stained with crystal violet for 30 min at room temperature, washed and imaged. Colonies of >50 cells were identified using an inverted microscope (olympus IX50; olympus Corp., Tokyo, japan) and counted.
Flow cytometry cell cycle assays. SW480 and HeLa stable cells were plated at a density of 4x10 5 cells per well in 6-well plates and cultured in medium without serum (starvation treatment) for 12 h to synchronize cell cycle progression. Cells were incubated in serum-containing growth medium for an additional 24-36 h and subsequently trypsinized, washed, fixed with 70% ice cold ethanol overnight at 4˚C. DnA was stained by incubating the cells in PBS containing PI (50 µg/ml) and Rnase A (50 µg/ml). The cell cycle distribution was determined by flow cytometric analysis using a MoFlo™ XDP High-Performance Cell Sorter (Beckman Coulter, Brea, CA, USA) and the data were analyzed using Summit v.5.2 software.
Co-immunoprecipitation (co-IP) assays.
HeK293 Flag-nC, HeK293 Flag-TSC22D2, SW480 Flag-nC, SW480 Flag-TSC22D2 stably transfected cells and HeK293T cells transiently cotransfected with Flag-TSC22D2 and HA-PKM2 were seeded in 100-mm dishes. The cells were lysed in modified lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM naCI, 50 mM naF, 1 mM na 3 Vo 4 , 30 mM sodium pyrophosphate, 0.5% nP-40 and 0.5 mM PMSF (Sigma) supplemented with an eDTA-free protease inhibitor cocktail (Roche). Lysates were incubated with 5 µg of primary antibody overnight at 4˚C. Then, 40 µl of a 1:1 slurry of protein A/G Plus-agarose (Santa Cruz, CA, USA) and a specific antibody were added to the cells for ≥4 h at 4˚C. The immunoprecipitates were washed four times with lysis buffer and boiled with sample loading buffer and then analyzed by western blotting.
Mass spectrometry. Proteins were resolved on a 10% polyacrylamide gel, stained with Coomassie Brilliant Blue (R250) and subjected to mass spectrometry. Briefly, the stained SDS-PAGe gels were scanned, and stained bands were excised, cut into small (<1 mm 3 ) pieces and washed three times by repetitive dehydration and hydration with acetonitrile and ammonium bicarbonate, respectively. Proteins were in-gel reduced in the presence of 25 mM DTT and 25 mM nH 4 HCo 3 for 1 h at 56˚C, immediately alkylated using 50 mM IAA and 25 mM nH 4 HCo 3 for 30 min at room temperature in the dark and digested overnight at 37˚C with 5 µg of trypsin in 25 mM nH 4 HCo 3 . Digested peptides were recovered, dried and resuspended in 50% CAn and 0.1% TFA. The peptide mixture was analyzed by nano-liquid chromatography-tandem mass spectrometry using an LTQ Velos-orbitrap MS (Thermo Scientific, Waltham, MA, USA) coupled to an Ultimate RSLC nano-LC system (Dionex). Briefly, Raw MS data files were processed using the Proteome Discoverer v.1.4 (Thermo Scientific). Processed files were searched against the Swiss-Prot human database using the Sequest HT search engine. Mass tolerances for precursor and fragment ions were set to 10 ppm and 0.8 Da, respectively, in the database searches. Peptide identification with false discovery rates <1% (q-value <0.01) were discarded.
Immunofluorescence. TSC22D2, HeK293, SW480 and HeLa cells grown on culture slides were maintained in a 35-mm dish.
After cultured for 24 h, the cells were washed with phosphatebuffered saline (PBS), fixed with 4% paraformaldehyde in PBS for 10 min, permeabilized with 0.25% Triton X-100 for 30 min and blocked in 5% bovine serum albumin (BSA) for 1 h at room temperature. Fixed cells were then incubated with rabbit anti-human TSC22D2 antibody (1:1,000) at 4˚C overnight, washed three times in PBS and stained with Alexa Fluor 488 donkey anti-rabbit IgG (Invitrogen, 1:1,000) for 2 h in the dark at room temperature. The cells were then incubated with DAPI to stain the nuclei and visualized using a confocal laser scanning microscope (olympus Corp.).
For the colocalization assays, HeK293T transfected with Flag-TSC22D2 and HA-PKM2 were incubated with the anti-Flag mouse monoclonal antibody (1:1,000) and the anti-PKM2 rabbit monoclonal antibody (1:1,000) at 4˚C overnight and subsequently stained with Alexa Fluor 488 donkey anti-mouse IgG (Invitrogen, 1:1,000) and Alexa Fluor 594 donkey anti-rabbit IgG (Invitrogen, 1:1,000) for 2 h at room temperature. After incubation with DAPI to stain the nuclei, the cells were visualized using a confocal laser scanning microscope (UltraView Vox; Perkin-elmer, Waltham, MA, USA).
Statistical analysis. The experiments were repeated at least three times. All data are presented as the mean ± standard deviation. Paired Student's t-test (two-tailed) and unpaired Student's t-test (two-tailed) were performed to compare the means of two samples unless otherwise indicated. A p-value <0.05 was considered statistically significant. All statistical analyses were performed using the GraphPad Prism software (Graphpad Software, Inc.).
Results
Expression of TSC22D2 is decreased in colorectal cancer samples. We focused on human colorectal cancer in this study because it was the most frequent malignancy in the multicancer family. We first evaluated the expression of TSC22D2 transcripts in colorectal cancer by interrogating the public gene expression Geo databases (GSe8671, GSe32323 and GSe24514) and found that the expression of TSC22D2 was lower in human colorectal cancer samples than in non-tumor samples (Fig. 1A) . To confirm these observations, the expression of TSC22D2 was evaluated in 14 pairs of human CRC samples (primary tumor tissues and paired adjacent non-tumor tissues). TSC22D2 expression was reduced in 13 of 14 (92.9%) of colorectal tumors compared with the paired adjacent non-tumor tissues (Fig. 1B, p=0 .015), consistent with the data provided by the Geo database. These results suggest that TSC22D2 plays a suppressor role in CRC tumorigenesis.
TSC22D2 suppresses CRC cell growth.
To investigate the function of TSC22D2 in colorectal cancer, the full-length TSC22D2 gene tagged with three Flag tags was cloned into the pIReSneo3 plasmid and stably transfected into SW480 and HeLa cells. The expression of TSC22D2 was confirmed by qRT-PCR and western blot analysis ( Fig. 2A) . Immunofluorescence assays demonstrated that TSC22D2 predominantly localized to the cytoplasm under steady state conditions (Fig. 2B) . Cell proliferation assays and clone formation assays were conducted to investigate the effect of TSC22D2 on cell proliferation. TSC22D2-overexpressing cells exhibited a significantly slower growth rate (Fig. 3A) and a reduced number of clones (Fig. 3B) compared with control cells, indicating that TSC22D2 functions as a suppressor in CRC cell growth. Furthermore, flow cytometry (FCM) revealed that TSC22D2 induced a substantial increase in the proportion of cells at the G0/G1 phase and a concomitant decrease in the proportion of cells at the S phase of the cell cycle (Fig. 3C) . These results indicate that TSC22D2 induces cell cycle arrest at the G0/G1 phase.
Identification of TSC22D2 binding partners.
To explore the underlying mechanism by which TSC22D2 exerts its tumorsuppressive function, we performed co-IP assays (Fig. 4A) and LC-MS/MS analysis (Fig. 4B ) in SW480 and HeK293 cells stably transfected with TSC22D2. We identified 90 and 79 candidate proteins in SW480 and HeK293 samples, respectively (Fig. 4C ). There were 27 overlapping results for proteins associated with metabolism (PKM2, ATP5A1, LDH and eno1), stress response and inflammation (STK39, HSPD1, HSP90AA1 and HSP90AB1), cell proliferation (nRBP1, PKM2, yWHAQ, LDHB, PCnA and PHB2), apoptosis (HSPD1, CAPn1, DnAjA1, HSP90AA1 and RPS3) and migration/metastasis (yWHAQ, HSPD1 and PHB2) between the 2 cell lines (Fig. 4D and Table Ⅰ ). These findings suggest that TSC22D2 plays a role in these biological pathways in cancer cells.
TSC22D2 physically associates with PKM2.
We selected PKM2, a glycolytic enzyme that catalyzes the conversion of phosphoenopyruvate (PeP) and ADP to pyruvate and ATP for further analysis due to its relatively high mass spectrometry score and its previously reported role in cancer cell growth and survival (7) (8) (9) .
The interaction between PKM2 and TSC22D2 was further confirmed by IP analysis of HeK293T cells transfected with HA-tagged PKM2 and Flag-tagged TSC22D2 (Fig. 5A ). To 
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A collagen-specific molecular chaperone that plays enhances cell growth, migration and invasion a role in collagen biosynthesis TUBB2A Key participant in various processes, including mitosis and intracellular transport a growth advantage to tumors (11, 12) . To determine if the effect of TSC22D2 on cell growth is mediated by PKM2, we evaluated the expression of PKM2 and observed that there were no significant changes in PKM2 expression at the mRnA and protein level in cells overexpressing TSC22D2 (Fig. 6A) . PKM2 predominantly localizes to the cytosol and plays an important role in metabolic functions. Recently, several independent studies demonstrated that PKM2 can translocate to the nucleus and induce the expression of gene products required for tumorigenesis by activating multiple transcription factors (13) (14) (15) (16) (17) (18) . Thus, we asked whether TSC22D2 could affect the nuclear function of PKM2. A subcellular fractionation analysis was performed, and a slight but significant decrease in the nuclear levels of PKM2 was observed in TSC22D2-overexpressing cells compared with the control cells (Fig. 6B) .
Cyclin D1, a key regulator required for the G1/S cell cycle transition, was reported to be a downstream gene of nuclear PKM2 (15, 16) . Therefore, we next investigated the effect of TSC22D2 on cyclin D1 expression. Intriguingly, TSC22D2 repressed the expression of cyclin D1 at both mRnA and protein levels ( Fig. 6C and D) , suggesting that TSC22D2 might inhibit cell growth by the influence on nuclear PKM2 and cyclin D1.
Discussion
We previously identified a novel cancer-associated gene, TSC22D2, by performing genome-wide linkage analysis and exome sequencing in samples derived from a multi-cancer family. TSC22D2 is a member of the TSC-22 domain family of proteins that are characterized by a carboxy-terminal leucine zipper and an adjacent TSC-box. However, its role in tumorigenesis remains largely unclear. In this study, we demonstrated that TSC22D2 is expressed at low levels in CRC and that TSC22D2 overexpression significantly inhibited the growth rate of cancer cells. Taken together, these results suggest that TSC22D2 might play a suppressive role in tumorigenesis.
Members of the TSC22 domain family are reported to interact with other proteins to form macromolecular complexes associated with a broad range of biological processes. TSC22D1 (also referred as TSC-22) binds to p53 and protects it from poly-ubiquitination-mediated degradation (2), it can enhance TGF-β signaling by associating with Smad4 (3). TSC22D3 (commonly referred to as GILZ) exhibits multiple biological functions that are dependent on its interaction with other proteins, including nF-κB, Ras and p53 (4) (5) (6) . TSC22D4 is capable of heterodimerizing with apoptosis-inducing factor (AIF) and might participate in apoptosis (19) . However, proteins that interact with TSC22D2 have not been identified.
In this study, we conducted co-IP assays combined with LC-MS/MS approaches to identify TSC22D2-interacting proteins. The results were enriched for proteins associated with the regulation of gene transcription, suggesting that TSC22D2 plays a role in transcription. TSC22 domain proteins have a classic leucine zipper and a TSC-Box structure. The leucine zipper might be a characteristic of a novel category of DnA binding proteins (20) (21) (22) and the TSC-box is essential for nuclear localization and transcriptional activity (23) . Based on these observations, TSC22 domain proteins are considered to be putative transcription factors. They primarily localize to the cytoplasm, but in response to specific stimuli, they can also translocate to the nucleus. Previous studies have demonstrated that TSC22D1 can translocate to the nucleus and suppress cell division in response to anti-proliferative stimuli (24, 25) . TSC22D1 and TSC22D3 transcriptional activity has been previously reported, and the transcriptional activity of TSC22D2 has yet to be further confirmed.
our analysis revealed that TSC22D2 interacts with multiple proteins associated with metabolism (PKM2, ATP5A1, LDHB and eno1), the stress response and inflammation (STK39, HSPD1, HSP90AA1 and HSP90AB1), cell proliferation (nRBP1, PKM2, yWHAQ, LDHB, PCnA and PHB2), apoptosis (HSPD1, CAPn1, DnAjA1, HSP90AA1 and RPS3) and migration/metastasis (yWHAQ, HSPD1 and PHB2) ( Table I) , implying that the function of TSC22D2 in tumor cells might be mediated by these processes. Moreover, the interaction between nRBP1 and TSC22D2 was inadvertently previously reported (26) . In addition, TSC22 domain proteins have been shown to homodimerize and heterodimerize with other family members (27) . In this study, western blotting and mass spectrometry analyses revealed that TSC22D2 primarily exists as a dimer, but that it might also heterodimerize with TSC22D4.
Given that TSC22D2 was capable of inhibiting the growth of cancer cells, we focused on the PKM2 gene, which was previously reported to be required for tumor growth (7) (8) (9) . Pyruvate kinase M2 (PKM2) is a pyruvate kinase that regulates the final rate-limiting step of glycolysis by catalyzing the transfer of a phosphate group from phosphoenolpyruvate (PeP) to ADP to generate pyruvate and ATP. PKM2 exhibits active pyruvate kinase activity as well as protein kinase activity that is primarily associated with transcriptional regulation (reviewed in refs. 11, 12) . elevated PKM2 expression is currently considered to be a common characteristic of cancers.
PKM2 primarily localized to the cytoplasm. In addition to its well characterized role in glycolysis, PKM2 can translocate to the nucleus to stimulate the activity of multiple transcription factors, including HIF-1, STAT3, β-catenin and oct-4, thereby increasing the expression of gene products that are required for tumor growth (16) (17) (18) 28) . For example, activation of eGFR in human glioblastoma cells induces the nuclear translocation of PKM2. In addition, the interaction between PKM2 and β-catenin transactivates factors that induce HDAC3 removal from the CCnD1 promoter, histone H3 acetylation and cyclin D1 expression (16) . An increasing body of evidence indicates that the nuclear translocation of PKM2 promotes the Warburg effect and tumorigenesis (13) (14) (15) (16) (17) (18) . In this study, we found that TSC22D2 did not regulate the total PKM2 protein levels, but that it decreased the level of nuclear PKM2. Although some studies have suggested that PKM2-interacting proteins impair PKM2 nuclear translocation by altering the balance between its monomer, dimer and tetramer forms or by mediating epigenetic modifications (14, 29) , further studies are required to confirm the mechanism by which TSC22D2 regulates the nuclear PKM2 level.
In conclusion, this is the first study to report the tumor suppressor role of TSC22D2 in cancer and to identify putative TSC22D2-interacting proteins using interactome analysis. The candidate interactions that we identified provide important clues that will facilitate future studies exploring TSC22D2 functions. The interaction between TSC22D2 and PKM2 may partially account for the growth suppressor function of TSC22D2. It is important to note that further studies of TSC22D2 complexes are required for gaining additional insight into the functions and precise mechanisms associated with TSC22D2 in cancer.
